TrialBlood advances2022

Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA.

Alex F Herrera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.